Evidence map›Paper›PMID 29218869›Full record

ArticlePacific Symposium on Biocomputing. Pacific Symposium on Biocomputing2018

Chemical reaction vector embeddings: towards predicting drug metabolism in the human gut microbiome.

Emily K Mallory, Ambika Acharya, Stefano E Rensi, Peter J Turnbaugh, Roselie A Bright, Russ B Altman

Open access · goldAbstract read
In one paragraph

Article in Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Computational analysis of the gut microbiota-mediated drug metabolism.Computational and structural biotechnology journal · 2025
    Article
  2. Review
  3. Integrating the gut microbiome and pharmacology.Science translational medicine · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Role of Gut Microbiota in the Pharmacological Effects of Natural Products.Evidence-based complementary and alternative medicine : eCAM · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Emily K MalloryBiomedical Informatics Training Program, Stanford University, Stanford, CA 94305, USA.
Ambika Acharya
Stefano E Rensi
Peter J Turnbaugh
Roselie A Bright
Russ B Altman
Stanford University · USUniversity of California, San Francisco · US

Funding

UCSF-Stanford Center of Excellence in Regulatory Science and InnovationU01FD005978 · FDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALTMAN, RUSS BIAGIO, GIACOMINI, KATHLEEN M · 2016 to 2025
$34.5M
POSTDOCTORAL TRAINING IN MEDICAL INFORMATION SCIENCEST15LM007033 · NLM · STANFORD UNIVERSITY · PI SYLVIA KATINA PLEVRITIS · 1985 to 2026
$25.5M
PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
THE STANFORD PHARMACOGENETICS KNOWLEDGE BASEU01GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO · 2000 to 2009
$24.0M
Text Mining for High-fidelity Curation and Discovery of Gene-drug-phenotype RelationshipsR01LM005652 · NLM · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO · 2000 to 2018
$6.2M
Predicting and preventing drug metabolism by the human gut microbiomeR01HL122593 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Peter James Turnbaugh · 2016 to 2026
$5.7M
UCSF-Stanford Center of Excellence in Regulatory Science and InnovationU01FD004979 · FDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALTMAN, RUSS BIAGIO, GIACOMINI, KATHLEEN M · 2014 to 2016
$5.4M
Undergraduate Summer Research Experiences Support for Combining systems biology and structural biology to find new therapeuticsR01GM102365 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO · 2012 to 2021
$3.0M
Integrating literature and experimental data for druggability methodsF31LM012354 · NLM · STANFORD UNIVERSITY · PI MALLORY, EMILY KATHRYN · 2016 to 2017
$76k
FDA HHS U01 FD004979FDA HHS U01 FD005978NHLBI NIH HHS R01 HL122593NIGMS NIH HHS R01 GM102365NIGMS NIH HHS R24 GM061374NIGMS NIH HHS U01 GM061374NLM NIH HHS F31 LM012354NLM NIH HHS R01 LM005652NLM NIH HHS T15 LM007033
6 · The paper itself

Abstract

Bacteria in the human gut have the ability to activate, inactivate, and reactivate drugs with both intended and unintended effects. For example, the drug digoxin is reduced to the inactive metabolite dihydrodigoxin by the gut Actinobacterium E. lenta, and patients colonized with high levels of drug metabolizing strains may have limited response to the drug. Understanding the complete space of drugs that are metabolized by the human gut microbiome is critical for predicting bacteria-drug relationships and their effects on individual patient response. Discovery and validation of drug metabolism via bacterial enzymes has yielded >50 drugs after nearly a century of experimental research. However, there are limited computational tools for screening drugs for potential metabolism by the gut microbiome. We developed a pipeline for comparing and characterizing chemical transformations using continuous vector representations of molecular structure learned using unsupervised representation learning. We applied this pipeline to chemical reaction data from MetaCyc to characterize the utility of vector representations for chemical reaction transformations. After clustering molecular and reaction vectors, we performed enrichment analyses and queries to characterize the space. We detected enriched enzyme names, Gene Ontology terms, and Enzyme Consortium (EC) classes within reaction clusters. In addition, we queried reactions against drug-metabolite transformations known to be metabolized by the human gut microbiome. The top results for these known drug transformations contained similar substructure modifications to the original drug pair. This work enables high throughput screening of drugs and their resulting metabolites against chemical reactions common to gut bacteria.

Indexed as

BacteriaBiotransformationCluster AnalysisComputational BiologyDatabases, PharmaceuticalDrug Evaluation, PreclinicalGastrointestinal MicrobiomeHigh-Throughput Screening AssaysHumansPharmaceutical PreparationsQuantitative Structure-Activity RelationshipStochastic ProcessesPharmaceutical Preparations

Identifiers

PMID29218869
PMCPMC5771676
OpenAlexW2770598293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.